Pure Global
NCT06392425

Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease

Assiut University·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Kidney Diseases
Drug/Device/Intervention
caspase 3 and ADAM 17 biomarkers
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Assiut University
Timeline & enrollment
Phase
N/A
Start date
Apr 26, 2024
End date
Oct 31, 2027
Enrollment
90 participants
Primary outcome

To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and Caspase 3 measurement in chronic kidney disease patients

Summary

1. To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and
 Caspase 3 measurement in chronic kidney disease patients
 
 2. Study relationship of serum ADAM 17 and Caspase 3 to stages of chronic kidney disease
 
 3. Compare serum ADAM 17 and Caspase 3 levels in Diabetic Chronic kidney disease patients
 and Non Diabetic Chronic kidney disease patients

ICD-10 classifications
Chronic kidney diseaseChronic kidney disease, unspecifiedChronic kidney disease, stage 1Chronic kidney disease, stage 4Chronic kidney disease, stage 2
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06392425
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06392425 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Chronic Kidney Diseases. Target enrollment is 90 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.